×
Beam Therapeutics EBIT 2019-2024 | BEAM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Beam Therapeutics ebit from 2019 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
Beam Therapeutics EBIT 2019-2024 | BEAM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Beam Therapeutics ebit from 2019 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$147B
Gilead Sciences (GILD)
$116B
Bristol Myers Squibb (BMY)
$115.8B
Vertex Pharmaceuticals (VRTX)
$110.2B
CSL (CSLLY)
$81.9B
Regeneron Pharmaceuticals (REGN)
$74.7B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$38.6B
Alnylam Pharmaceuticals (ALNY)
$34.4B
BioNTech SE (BNTX)
$27.6B
Illumina (ILMN)
$22.3B
BeiGene (ONC)
$21.7B
Biogen (BIIB)
$20.8B
Moderna (MRNA)
$14.8B
Insmed (INSM)
$14B
Incyte (INCY)
$13.9B
Genmab (GMAB)
$13.9B
Genmab (GNMSF)
$13.9B
Intra-Cellular Therapies (ITCI)
$13.5B
Bio-Techne Corp (TECH)
$12.5B
BioMarin Pharmaceutical (BMRN)
$11.8B
Sarepta Therapeutics (SRPT)
$11.1B
Vaxcyte (PCVX)
$10.8B
QIAGEN (QGEN)
$10.8B
Exact Sciences (EXAS)
$10.1B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.8B
Exelixis (EXEL)
$9.4B
Repligen (RGEN)
$9.3B
Roivant Sciences (ROIV)
$8.1B